Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Cipla Limited, is a listed public company incorporated on 17 August, 1935. It is classified as a public limited company and is located in Mumbai City, Maharashtra. It's authorized share capital is INR 175.00 cr and the total paid-up capital is INR 161.51 cr.
Cipla Limited's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has increased by 12.66% over the previous year. At the same time, it's book networth has increased by 9.44%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
4.96%
18.23%
62.22%
13.54%
12.53%
5.45
3.03
7.21
4.38
2.45
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(159)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Whole-time Director | Samina Hamied
Shareholder
|
00027923 | 9 years |
| Director | Yusuf Khwaja Hamied
Shareholder
|
00029049 | 52 years |
| Director | Mustafa Khwaja Hamied
Shareholder
|
00029084 | 47 years |
| Director | Prathivadibhayankara Rajagopalan Ramesh | 01915274 | 3 years |
| Managing Director | Umang Vohra
Shareholder
|
02296740 | 8 years |
| Director | Sharmila Nitin Paranjpe | 02328770 | 0 years |
| Director | Punita Lal | 03412604 | 10 years |
| Director | Robert Stewart | 03515778 | 4 years |
| Director | Adil Zainulbhai | 06646490 | 10 years |
| CS | Rajendra Kumar Chopra
Shareholder
|
<HIDDEN> | 8 years |
| Director | Abhijit Jagdish Joshi | 07115673 | 0 years |
| CFO | Ashish Adukia | <HIDDEN> | 2 years |
| Director | Mandar Purushottam Vaidya | 09690327 | 2 years |
| Director | Balram Bhargava | 10479707 | 1 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| HAMSONS LABORATORIES PRIVATE LIMITED |
Converted to LLP and Dissolved
|
40.0 L | 1 | Maharashtra |
| TWIST PHARMA PRIVATE LIMITED |
Strike Off
|
25.0 L | 1 | Maharashtra |
| CIPLA HEALTH LIMITED |
Active
|
2.3 Cr | 2 | Maharashtra |
| GLOBUS HEALTHCARE LIMITED |
Strike Off
|
5.0 L | 1 | Maharashtra |
| M K HAMIED FOUNDATION |
Active
|
1.0 L | 1 | Maharashtra |
| HOUSING DEVELOPMENT FINANCE CORPORATION LIMITED |
Amalgamated
|
370.3 Cr | 1 | Maharashtra |
| THE CLEARING CORPORATION OF INDIA LIMITED |
Active
|
50.0 Cr | 1 | Maharashtra |
| FORUM FOR INDIAN ACCOUNTING RESEARCH |
Active
|
0.0 | 1 | Telangana |
| ITC HOTELS LIMITED |
Active
|
83.0 Cr | 1 | West Bengal |
| AIX CONNECT PRIVATE LIMITED |
Amalgamated
|
4,195.0 Cr | 1 | Haryana |
| LARSEN AND TOUBRO LIMITED |
Active
|
274.9 Cr | 1 | Maharashtra |
| CROMPTON GREAVES CONSUMER ELECTRICALS LIMITED |
Active
|
128.7 Cr | 1 | Maharashtra |
| TEJAS NETWORKS LIMITED |
Active
|
171.3 Cr | 1 | Karnataka |
| AIR INDIA LIMITED |
Active
|
35,360.2 Cr | 1 | Haryana |
| NSE INVESTMENTS LIMITED |
Active
|
826.0 Cr | 1 | Maharashtra |
| AIR INDIA EXPRESS LIMITED |
Active
|
1,017.1 Cr | 1 | Haryana |
| NESTLE INDIA LIMITED |
Active
|
96.4 Cr | 1 | Delhi |
| I-VEN PHARMA CAPITAL LIMITED |
Under Liquidation
|
8.9 L | 1 | Karnataka |
| STEMPEUTICS RESEARCH PRIVATE LIMITED |
Active
|
59.7 Cr | 1 | Karnataka |
| DOOR STEP SCHOOL FOUNDATION |
Active
|
0.0 | 1 | Maharashtra |
| OPEN NETWORK FOR DIGITAL COMMERCE |
Active
|
754.0 Cr | 1 | Delhi |
| C3 MEDICARE PRIVATE LIMITED |
Active
|
1.0 L | 1 | Maharashtra |
| SAMSHIKSHA FOUNDATION |
Active
|
0.0 | 1 | Delhi |
| UNNATI EMPLOYMENT NETWORK |
Active
|
2.5 Cr | 1 | Delhi |
| NETWORK18 MEDIA & INVESTMENTS LIMITED |
Active
|
523.5 Cr | 1 | Maharashtra |
| RELIANCE RETAIL VENTURES LIMITED |
Active
|
7,011.2 Cr | 1 | Maharashtra |
| TV18 BROADCAST LIMITED |
Active
|
342.9 Cr | 1 | Maharashtra |
| PIRAMAL FOUNDATION |
Active
|
0.0 | 1 | Maharashtra |
| RELIANCE RETAIL LIMITED |
Active
|
8,987.0 Cr | 1 | Maharashtra |
| VIACOM 18 MEDIA PRIVATE LIMITED |
Active
|
428.3 Cr | 1 | Maharashtra |
| STEP UP CHARITABLE FOUNDATION |
Active
|
80,000.0 | 1 | Maharashtra |
| NAVIN FLUORINE INTERNATIONAL LIMITED |
Active
|
9.9 Cr | 1 | Maharashtra |
| BHARTI TELE COM LTD |
Not available for efiling
|
0.0 | 1 | Delhi |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| The Cipla Empowerment Trust | South Africa | - | - |
| Cipla Health Employees Stock Option Trust | India | - | - |
| Aspergen Inc | United States | - | - |
| Mirren (Pty) Limited | South Africa | - | - |
| Medpro Pharmaceutica (Pty) Limited | South Africa | - | - |
| Cipla Select (Pty) Limited | South Africa | - | - |
| Cipla Medpro Botswana (Pty) Limited | Botswana | - | - |
| Cipla-Medpro Distribution Centre (Pty) Limited | South Africa | - | - |
| Cipla-Medpro (Pty) Limited | South Africa | - | - |
| Cipla Medpro Manufacturing (Pty) Limited | South Africa | - | - |
| Cipla Dibcare (Pty) Limited | South Africa | - | - |
| Cipla Therapeutics Inc | United States | - | - |
| Cipla Kenya Limited | Kenya | - | - |
| Madison Pharmaceuticals Inc. | United States | - | - |
| Cipla Technologies LLC | United States | - | - |
| Exelan Pharmaceuticals Inc. | United States | - | - |
| InvaGen Pharmaceuticals Inc. | United States | - | - |
| Cipla USA Inc. | United States | - | - |
| Cipla (China) Pharmaceutical Co., Limited | China | - | - |
| Cipla (Jiangsu) Pharmaceutical Co., Limited | China | - | - |
| Cipla Colombia SAS | Colombia | - | - |
| Cipla Philippines Inc. | Philippines | - | - |
| Cipla EU Limited | United Kingdom | - | - |
| Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda. | Brazil | - | - |
| Cipla Australia Pty Limited | Australia | - | - |
| Cipla Maroc SA | Morocco | - | - |
| Breathe Free Lanka (Private) Limited | Sri Lanka | - | - |
| Cipla Malaysia Sdn. Bhd. | Malaysia | - | - |
| Cipla Gulf FZ – LLC | United Arab Emirates | - | - |
| Cipla Middle East Pharmaceuticals FZ-LLC | United Arab Emirates | - | - |
| Cipla Medica Pharmaceutical and Chemical Industries Limited | Yemen | - | - |
| Saba Investment Limited | United Arab Emirates | - | - |
| Cipla Holding B.V. | Netherlands | - | - |
| Cipla Europe NV | Belgium | - | - |
| Cipla Algerie | Algeria | - | - |
| Meditab Holdings Limited | Mauritius | - | - |
| Cipla Quality Chemical Industries Limited | Uganda | - | - |
| Cipla Medpro South Africa (Pty) Limited | South Africa | - | - |
| CIPLA DIGITAL HEALTH LIMITED | Maharashtra | 2022 | ₹ 30.0 Cr |
| CIPLA PHARMACEUTICALS LIMITED | Maharashtra | 2019 | ₹ 72.0 Cr |
| CIPLA PHARMA AND LIFE SCIENCES LIMITED | Maharashtra | 2008 | ₹ 258.7 Cr |
| CIPLA HEALTH LIMITED | Maharashtra | 2015 | ₹ 2.3 Cr |
| SITEC LABS LIMITED | Maharashtra | 2000 | ₹ 1.6 L |
| GOLDENCROSS PHARMA LIMITED | Maharashtra | 2000 | ₹ 4.6 L |
| MEDISPRAY LABORATORIES PRIVATE LIMITED | Goa | 1992 | ₹ 5.1 L |
| MEDITAB SPECIALITIES LIMITED | Maharashtra | 1996 | ₹ 71.2 L |
| JAY PRECISION PHARMACEUTICALS PRIVATE LIMITED | Maharashtra | 2012 | ₹ 4.0 Cr |
| Actor Pharma (Pty) Limited | South Africa | - | - |
| Mexicip S.A. de C.V. | Mexico | - | - |
The incorporation date of CIPLA LIMITED is 17 August, 1935
The authorized share capital of CIPLA LIMITED is INR ₹ 175.0 Cr.
The paid-up capital of CIPLA LIMITED is INR ₹ 161.5 Cr.
The registered address of CIPLA LIMITED is Cipla House, Peninsula Business Park Ganpatrao Kadam Marg, Lower Parel NA Mumbai Mumbai City Maharashtra - 400013
The CIN number of CIPLA LIMITED is L24239MH1935PLC002380.
Expand
Delete
Collapse
See
details
